We are live on ! Find out more
PAP

Persistent Asset Partners Portfolio holdings

AUM $268M
1-Year Est. Return 158.98%
This Fund
S&P 500
This Quarter Est. Return
+11.27%
1 Year Est. Return
+158.98%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$135M
AUM Growth
+$15.6M
Cap. Flow
+$220M
Cap. Flow %
163.5%
Top 10 Hldgs %
31.52%
Holding
253
New
80
Increased
47
Reduced
36
Closed
74

Top Buys

1
HUM icon
Humana
HUM
+$4.21M
2
AMGN icon
Amgen
AMGN
+$3.4M
3
EHC icon
Encompass Health
EHC
+$3.34M
4
SLNO
Soleno Therapeutics
SLNO
+$3.29M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$1.9M

Top Sells

1
CNC icon
Centene
CNC
+$10.3M
2
UNH icon
UnitedHealth
UNH
+$4.9M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$3.17M
4
IBIT icon
iShares Bitcoin Trust
IBIT
+$3M
5
CON
Concentra Group Holdings
CON
+$2.39M

Sector Composition

1 Healthcare 51.79%
2 Financials 16.59%
3 Materials 5%
4 Technology 2.34%
5 Energy 1.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRRK icon
76
Scholar Rock
SRRK
$6.33B
$507K 0.38%
14,314
+1,211
+9% +$38K
CFLT
77
DELISTED
Confluent
CFLT
$499K 0.37%
+20,000
New +$451K
SF
78
Stifel
SF
$11.8B
$487K 0.36%
+7,037
New +$432K
LLY icon
79
PUT
Eli Lilly
LLY
$1.05T
$474K 0.35%
34,600
+34,552
+71,983% +$26.8M
URGN icon
80
UroGen Pharma
URGN
$1.96B
$474K 0.35%
34,600
+17,029
+97% +$163K
ITOS
81
DELISTED
iTeos Therapeutics
ITOS
$474K 0.35%
+47,512
New +$383K
EHTH icon
82
eHealth
EHTH
$47.3M
$470K 0.35%
108,106
-39,209
-27% -$197K
PNFP icon
83
Pinnacle Financial Partners Inc
PNFP
$15.3B
$464K 0.34%
+4,207
New +$434K
JBIO
84
PUT
Jade Biosciences
JBIO
$1.27B
$452K 0.34%
12,437
+12,427
+124,270% +$423K
RARE icon
85
Ultragenyx Pharmaceutical
RARE
$2.88B
$452K 0.34%
+12,437
New +$448K
RDDT icon
86
Reddit
RDDT
$34.9B
$452K 0.34%
3,000
– –
ORCL icon
87
Oracle
ORCL
$364B
$437K 0.32%
2,000
– –
XNTK icon
88
CALL
State Street SPDR NYSE Technology ETF
XNTK
$2.05B
$432K 0.32%
+1,971
New +$409K
RARE icon
89
PUT
Ultragenyx Pharmaceutical
RARE
$2.88B
$392K 0.29%
28,032
+27,712
+8,660% +$999K
VRDN icon
90
Viridian Therapeutics
VRDN
$1.99B
$392K 0.29%
28,032
-9,179
-25% -$125K
APGE icon
91
CALL
Apogee Therapeutics
APGE
$10.1B
$378K 0.28%
362
+69
+24% +$2.63K
MRK icon
92
Merck
MRK
$315B
$368K 0.27%
+4,647
New +$369K
BBIO icon
93
CALL
BridgeBio Pharma
BBIO
$15.9B
$353K 0.26%
303
– –
PCRX icon
94
Pacira BioSciences
PCRX
$1.01B
$324K 0.24%
13,575
+4,612
+51% +$116K
NPB
95
Northpointe Bancshares
NPB
$650M
$322K 0.24%
23,475
-41,721
-64% -$560K
TOWN icon
96
Towne Bank
TOWN
$3.34B
$321K 0.24%
+9,390
New +$313K
QCRH icon
97
QCR Holdings
QCRH
$1.63B
$319K 0.24%
4,695
-19,229
-80% -$1.29M
NVDA icon
98
CALL
NVIDIA
NVDA
$4.91T
$293K 0.22%
+560
New +$70.5K
RYAAY icon
99
Ryanair
RYAAY
$32.5B
$281K 0.21%
4,864
-14,084
-74% -$717K
ZK
100
DELISTED
Zeekr
ZK
$255K 0.19%
+10,000
New +$246K
2 3
4
5 6

Similar funds

VC
VarCov Co Darien, Connecticut $268M AUM
AL
AIP LLC New York $268M AUM 40.4% 1-Year Est. Return
FC
Foursixthree Capital New York $268M AUM 115.24% 1-Year Est. Return
NF
Nvest Financial Portsmouth, New Hampshire $268M AUM 22.87% 1-Year Est. Return
PF
Prosperitas Financial Valencia, California $268M AUM 32.64% 1-Year Est. Return
UI
Untitled Investments New York $269M AUM 11.35% 1-Year Est. Return
SSWM
Strait & Sound Wealth Management San Francisco, California $269M AUM 22.03% 1-Year Est. Return
AC
Applied Capital Little Rock, Arkansas $268M AUM 16.92% 1-Year Est. Return

Persistent Asset Partners's Q2 2025 Portfolio in Review

As of Q2 2025, Persistent Asset Partners held 253 positions worth $135M, up 13% from $119M the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Persistent Asset Partners deployed $220M of net new capital in Q2 2025, opening 80 new positions and adding to 47 existing holdings. Its largest new stake was Amgen: 12,000 shares worth $3.35M.

By sector, the portfolio is most concentrated in Healthcare at 52% of assets, down from 61% a quarter earlier, followed by Financials and Materials.

On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $3.17M trimmed.

  • Persistent Asset Partners's largest Q2 2025 buy was Amgen: 12,000 shares worth $3.35M.
  • Persistent Asset Partners added most to Humana in Q2 2025, an estimated $4.21M increase.
  • Persistent Asset Partners's biggest Q2 2025 reduction was Regeneron Pharmaceuticals, cutting an estimated $3.17M.
  • Persistent Asset Partners fully exited Centene in Q2 2025, selling an estimated $10.3M.
  • Persistent Asset Partners's ten largest holdings make up 32% of its $135M portfolio in Q2 2025.
  • Persistent Asset Partners opened 80 new positions and closed 74 in Q2 2025.
  • Persistent Asset Partners's portfolio value rose 13% quarter-over-quarter to $135M.

Based on Persistent Asset Partners's 13F filing for Q2 2025, filed 11 Aug 2025.